
The IMID Forum
Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.
Latest episodes

Jul 7, 2023 • 30min
Author Interview: Mark Russell
Professor Peter Nash from the Griffith University in Brisbane, is joined by Dr Mark Russell, a clinical research fellow at the Centre for Rheumatic Diseases, King’s College London to discuss his recent paper 'JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications'.

Jun 26, 2023 • 10min
Discussing Rheumatology: June 2023
Join Prof Iain McInnes as he reviews two interesting papers surrounding filgotinib and baricitinib. Our first paper today by Walter Reinisch and his colleagues highlight the latest update from the Phase 2 MANTA and MANTA-Ray studies, exploring the impact of filgotinib semen parameters and sex hormones in men with inflammatory diseases. In the second paper, David Simon and his team investigate the impact of baricitinib on volumetric bone mineral density and several other markers of bone health in RA patients.

Jun 14, 2023 • 22min
AxSpA Podcast: Secukinumab Optimisation & Ixekizumab Treatment for PAEs
Join Professors Atul Deodhar, Xenofon Baraliakos, Hideto Kameda, and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. Our first paper aimed to determine when the optimal time to start secukinumab treatment is demonstrated by a significant difference between baseline and post treatment BASDAI scores. Our second paper the goes on to evaluate a case report of a 45-year-old male, with AS, and adalimumab-induced refractory paradoxical palmoplantar pustulosis, after failure of prior secukinumab treatment.

Jun 3, 2023 • 19min
EULAR 2023 Highlights: Day 4
Join Professor Peter Nash as he goes through our top abstracts, posters, and presentations from Day 4 of EULAR 2023 today (Saturday 3 June).
They're all available right here on the CSF YouTube channel, so make sure you don't miss them!

Jun 2, 2023 • 27min
EULAR 2023 Highlights: Day 3
Join Professor Lorenzo Dagna as she goes through our top abstracts, posters, and presentations from Day 3 of EULAR 2023 today (Friday 2 June).
They're all available right here on the CSF YouTube channel, so make sure you don't miss them!

Jun 1, 2023 • 16min
EULAR 2023 Highlights: Day 2
Join Dr Sofia Ramiro as she goes through our top abstracts, posters, and presentations from Day 2 of EULAR 2023 today (Thursday 1st June).
They're all available right here on the CSF YouTube channel, so make sure you don't miss them!

May 31, 2023 • 10min
Discussing Rheumatology: May 2023
Join Prof Iain McInnes in today’s podcast, where he will be reviewing two papers that investigate treatments for RA patients.
In the first paper, Philip Conaghan and colleagues evaluate the effectiveness in a Bruton’s tyrosine kinase inhibitor in treating rheumatoid arthritis in patients with an inadequate response to methotrexate.
In the second paper, Vincenzo Venerito and his team assessed the recombinant zoster vaccine in rheumatoid arthritis patients that are treated with JAK inhibitors.

May 31, 2023 • 15min
EULAR 2023 Highlights: Day 1
Join Professor Xavier Mariette as he goes through our top abstracts, posters, and presentations from Day 1 of EULAR 2023 today (Wednesday 31 May).
They're all available right here on the CSF YouTube channel, so make sure you don't miss them!

May 26, 2023 • 12min
EULAR 2023 Preview Podcast
Join Professor Peter Nash as he previews our highlights this EULAR, introducing some of the top abstracts we’ve chosen so that you can better plan your time at what will be a busy and exciting congress.

May 15, 2023 • 27min
PsA Podcast: Guselkumab & Secukinumab – All the Latest in Efficacy & Safety
Join Professors Peter Nash, Laura Coates, and Frank Behrens as they discuss the latest top research in PsA. The papers covered in this topical discussion highlight two fascinating therapeutics used in PsA treatment. This includes the latest evaluation of the efficacy and safety of guselkumab in DISCOVER-1 patients with active PsA by prior use of TNFi, as well as the latest investigation into the efficacy of secukinumab in patients with dactylitis at baseline over 2 years.